Pneumocystis carinii (
P. carinii), which is one of the major pathogens in AIDS patients, is considered a fungus from results of molecular biological analysis. We made a couple of interesting observations concerned with the cross relationship between
P. carinii and fungi.
First, we detected (1→3)-beta-D-glucan (beta-glucan) in sera obtained from patients with
P. carinii pneumonia: Beta-glucan is one of the major components of the cyst wall of
P. carinii as well as the cell wall of fungi. There are several reports of beta-glucan being detected in sera obtained from patients with deep-seated mycosis. In four of the five
P. carinii pneumonia patients, the level of beta-glucan was elevated more than 300pg/m
l in their sera, and the level decreased along with clinical improvement.
Second, we found a new anti-
P. carinii agent which was under development as an anti-fungal drug: The cell wall of
P. carinii and fungi have a similar structure with a great deal of mannan backbone. Benanomicin A has antimycotic activity by binding to mannan. We examined the anti-pneumocystis activity of benanomicin A using mice with
P. carinii pneumonia. After completion of three weeks of treatment with or without 100mg/kg of benanomicin A, the mean number of cysts by high performance microscopic field in the lung was 4.9 in the treated group, and 206 in the control group. There was thus a statistical difference between the two. The result indicated that the agent had the potential to be a new anti-
P. carinii drug with a new mechanism of anti-
P. carinii action.
View full abstract